Specific binding of [3H]phencyclidine in rat central nervous tissue: further characterization and technical considerations.
S R Zukin, M L Fitz-Syage, R Nichtenhauser, R S Zukin
Brain Research January 10, 1983 DOI: 10.1016/0006-8993(83)91151-4 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Key points | Kinetic binding constants for PCP at its central nervous system receptor (kinetic KD 1.6 × 10(-7) M) agreed with equilibrium measurements, and the receptor showed stereospecificity, with (+)-ketamine four-fold more potent than (-)-ketamine in displacing bound [3H]PCP. Proteolytic enzymes inactivated the receptors, and receptor density was highest in subicular cortex and hippocampus and negligible in corpus callosum. |
Abstract
The interaction of phencyclidine (PCP) with its specific receptor sites in the central nervous system has been further characterized. Kinetic association and dissociation rate constants of 2.9 X 10(6) M-1 and 4.8 X 10(-1) min-1 were determined, yielding a kinetic KD of 1.6 X 10(-7) M, in agreement with the KD previously determined at equilibrium. Permissible separation time of 13 s was calculated from the kinetic data, well above the actual separation time of less than 10 s in the rapid filtration assay. Presoaking of filters in 0.01% poly-L-lysine eliminated displacable [3H]PCP adsorption to filter material. Binding data obtained via centrifugation assays was identical to that obtained with the rapid filtration method. Stereospecificity of the PCP receptor was demonstrated by the finding that (+)-ketamine is four-fold more potent than (-)-ketamine in displacing specifically bound [3H]PCP. Several proteolytic enzymes including trypsin, papain and thermolysin potently inactivated PCP receptors. Detailed regional distribution studies showed highest density of PCP receptors in subicular cortex and hippocampus, intermediate levels in hypothalamus, striatum, frontal cortex and cerebellum, lower levels in brainstem and spinal cord, and negligible levels in corpus callosum, a white-matter control area. Benzomorphan opiates with PCP-like behavioral effects interact with the PCP receptor. These data support the pharmacological relevance of the PCP receptor site as demonstrated by the rapid filtration method.
Citations in the library
Cited by 8
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- Phencyclidine-induced head-twitch response in rats treated chronically with methysergide. European Journal of Pharmacology January 20, 1987
- The Phencyclidine/N-Methyl-D-Aspartate (PCP/ NMDA) Model of Schizophrenia: Theoretical and Clinical Implications Psychiatric Annals March 1, 1993
- Phencyclidine treatment in mice: effects on phencyclidine binding sites and glutamate uptake in cerebral cortex preparations. Journal of neural transmission. General section 1993
- Specificity of phencyclidine-like drugs and benzomorphan opiates for two high affinity phencyclidine binding sites in guinea pig brain. Neuropharmacology September 1, 1990
and 3 more in the library